05 December 2024
05 December 2024
US police have confirmed that the CEO of the insurance subsidiary was fatally shot outside an investor conference by a masked assailant.
An open- label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.
The decision was supported by the outcomes from the Phase III ADRIATIC trial.
The decision was based on the positive outcomes of the Phase III programme.
The round was co-led by Deep Track Capital and Frazier Life Sciences.
Takeda will make an upfront payment of $200m to Keros.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
